Description

Description

Xiga-Met XR 5/500mg Tablet is an extended-release fixed-dose combination medicine used in the management of type 2 diabetes mellitus in adults. It combines Dapagliflozin, an SGLT2 inhibitor that helps the kidneys remove excess glucose through urine, with an extended-release form of Metformin that releases gradually over an extended period rather than all at once. This slow-release design allows for convenient once-daily dosing while aiming to reduce the digestive discomfort that can sometimes accompany immediate-release Metformin combinations. Xiga-Met XR is typically prescribed for patients who need the combined benefit of kidney-based glucose excretion and liver-based glucose reduction, particularly those who prefer a simplified once-a-day routine or who have experienced stomach-related side effects with immediate-release formulations. The pack contains 14 tablets, generally supporting a two-week course as guided by the prescribing doctor, and this medicine should always be used exactly as instructed given its controlled-release design.

Ingredients

Each Xiga-Met XR 5/500mg Tablet contains Dapagliflozin 5mg together with Metformin Hydrochloride 500mg in extended-release form. Dapagliflozin works by inhibiting the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion through urine, while the extended-release Metformin component is embedded within a controlled-release polymer matrix, commonly built using hydroxypropyl methylcellulose, that regulates the gradual dissolution and absorption of the medicine. Additional inactive ingredients typically include microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide, and a film coating that supports the tablet’s structure and appearance.

Dosage Form

This medicine is manufactured as a film-coated, extended-release oral tablet, formulated with a controlled-release matrix that allows the Metformin component to be absorbed gradually over several hours. The tablets are packed in blister strips that protect them from moisture and light, helping preserve the release mechanism’s integrity until the expiry date printed on the packaging.

Uses

Xiga-Met XR 5/500mg Tablet is used to manage blood sugar levels in adults with type 2 diabetes mellitus who benefit from a once-daily combination therapy with a smoother release profile. The Dapagliflozin component supports glucose control by promoting its excretion through urine, working independently of insulin, while the extended-release Metformin component provides a steady reduction in liver glucose production and gradually improves insulin sensitivity over the day. This formulation is often chosen for patients who need the added benefit of an SGLT2 inhibitor alongside Metformin but prefer the convenience and improved digestive tolerability associated with extended-release dosing. As with other combination therapies, it is generally used alongside dietary management, regular exercise, and consistent monitoring to support long-term blood sugar control.

How to Use

Xiga-Met XR 5/500mg Tablet should be taken exactly as prescribed by the doctor, typically once daily in the morning or with the main meal, depending on the specific instructions given. The tablet must always be swallowed whole with a glass of water and should never be crushed, broken, or chewed, as this could disrupt the extended-release mechanism and cause the medicine to be released more quickly than intended. Patients may occasionally notice a tablet-shaped residue in their stool, which is simply the depleted shell of the extended-release matrix and is considered a normal, harmless occurrence. Maintaining adequate hydration is also important while on this medicine, given the increased urine output associated with the Dapagliflozin component. Doses should not be doubled to make up for a missed one; instead, the missed dose should be taken as soon as remembered unless the next dose is close.

Side Effects

Xiga-Met XR is generally associated with a gentler digestive tolerability profile compared to immediate-release combinations, though side effects can still occur. Commonly reported effects linked to Metformin include mild nausea, occasional diarrhea, or a metallic taste, which often ease as the body adjusts. Effects associated with the Dapagliflozin component may include increased urination, genital yeast infections, and urinary tract infections due to higher glucose content in urine. Some patients may also experience mild dizziness or symptoms of fluid loss if hydration is insufficient. In rare but serious cases, symptoms of lactic acidosis (unusual muscle pain, difficulty breathing, unexplained fatigue) related to Metformin, or euglycemic diabetic ketoacidosis (nausea, vomiting, abdominal pain) related to Dapagliflozin, may develop and require urgent medical attention. Any severe or persistent symptoms should be discussed with a doctor promptly.

Pregnancy & Breastfeeding

Xiga-Met XR 5/500mg Tablet is generally not recommended during pregnancy, as both the SGLT2 inhibitor and biguanide components are typically replaced with alternative treatments once pregnancy is confirmed, since diabetes management during pregnancy usually follows a different treatment protocol. Women who are pregnant, planning a pregnancy, or currently breastfeeding should inform their doctor before starting or continuing this medicine so that safer alternatives can be considered. Breastfeeding mothers should also seek medical guidance, as the safety of this combination during lactation has not been clearly established.

Storage Instructions

Store Xiga-Met XR 5/500mg Tablets in a cool, dry place away from direct sunlight, heat, and moisture, ideally at a temperature below 30°C. Keep the tablets in their original blister packaging until ready for use to protect the controlled-release coating, and store them securely out of the reach and sight of children and pets. Avoid storing this medicine in humid areas such as bathrooms, and do not freeze the tablets. Always check the expiry date before use, and dispose of any expired or unused tablets responsibly through a proper medicine disposal program rather than household waste or drains.

FAQS

Q1. What does “XR” mean in Xiga-Met XR?
XR stands for extended-release, meaning the Metformin component is released gradually over time rather than all at once, supporting once-daily dosing.

Q2. Can this tablet be crushed or split for easier swallowing?
No, it should always be swallowed whole, as crushing or splitting can interfere with the controlled-release mechanism and change how quickly the medicine is absorbed.

Q3. Does the Dapagliflozin component still carry the same precautions in this XR formulation?
Yes, the risk of urinary infections and the need for adequate hydration remain relevant, since these effects come from the Dapagliflozin component regardless of the Metformin release format.

Q4. Is it normal to notice something resembling the tablet in the stool?
Yes, this is simply the leftover shell of the extended-release matrix after the medicine has been absorbed, and it is considered a normal and harmless occurrence.

Q5. Does this XR formulation reduce digestive side effects?
Many patients experience better digestive tolerability with extended-release Metformin compared to immediate-release versions, though individual responses can vary.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.